Welcome to our dedicated page for West Pharm Svcs SEC filings (Ticker: WST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The West Pharmaceutical Services, Inc. (NYSE: WST) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. West is a Pennsylvania corporation in the surgical and medical instrument manufacturing industry, focused on injectable drug administration for pharmaceutical, biotechnology and generic drug customers.
West’s SEC filings include annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Recent 8-K filings have covered topics such as second- and third-quarter 2025 financial results, updated revenue and adjusted-diluted EPS guidance, and changes in senior leadership, including the appointment of a new Senior Vice President & Chief Financial Officer and the planned departure of a senior legal executive. Other 8-Ks reference the furnishing of earnings press releases and investor presentation materials.
For investors analyzing WST, the 10-K and 10-Q filings contain detailed information on the Proprietary Products and Contract-Manufactured Products segments, High-Value Product Components and Delivery Devices, capital spending, cash flow, and risk factors. Form 8-K filings provide timely updates on material events, including financial results, dividends, guidance changes and executive compensation arrangements.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping users quickly identify segment performance, guidance revisions and notable risk disclosures. Real-time updates from the SEC’s EDGAR system ensure that new West filings appear promptly. Users can also review filings that relate to executive appointments, compensation terms and other governance matters, which are often detailed in exhibits to Form 8-K. This page serves as a focused resource for reviewing West Pharmaceutical Services’ regulatory history and ongoing reporting.
WEST PHARMACEUTICAL SERVICES INC senior vice president Rodolphe Jean Poussot reported equity compensation activity involving restricted stock units and common shares. On February 20, 2026, he exercised 383.382 restricted stock units, which converted into the same number of common shares at no cash cost.
Following this conversion, his directly held common stock position increased, then 129.545 shares of common stock were automatically withheld at
West Pharmaceutical Services VP & Treasurer Charles Witherspoon reported equity award activity involving restricted stock units and common shares. On February 20, 2026, 60.220 restricted stock units converted into 60.220 shares of common stock on a one-for-one basis, increasing his directly held common shares to 1,429.966.
To cover tax obligations related to the vesting, 22.069 common shares were disposed of at $241.12 per share through a tax-withholding transaction, leaving him with 1,407.897 directly owned common shares. After the transaction, he also directly held 177.644 restricted stock units, which can convert into common stock in the future under the award terms.
West Pharmaceutical Services VP and Chief Accounting Officer Chad Winters exercised restricted stock units into common stock and had shares withheld to cover taxes. On February 20, 2026, he converted 89.328 restricted stock units into the same number of common shares at $0.00 per share, increasing his direct common stock holdings to 1,552.994 shares. On the same date, 30.184 common shares were disposed of at $241.12 per share in a tax-withholding transaction, leaving him with 1,522.810 common shares directly owned. Footnotes state these restricted stock units convert to common stock on a one-for-one basis and relate to a prior grant that vests in four equal annual installments.
West Pharmaceutical Services senior vice president Rodolphe Jean Poussot reported equity compensation activity involving restricted stock units and common shares. He acquired 82.299 common shares through the exercise or conversion of restricted stock units, which convert into common stock on a one-for-one basis.
Following this conversion, 27.809 common shares were disposed of at 248.26 per share to cover tax obligations through a tax-withholding disposition, rather than an open-market sale. After these transactions, his direct common stock holdings totaled 307.398 shares, and he held 247.899 restricted stock units directly. A prior grant of 329 restricted stock units vests in four equal annual installments, including dividend equivalents.
West Pharmaceutical Services VP & Treasurer Charles Witherspoon reported two stock transactions in company common stock. He acquired 115.910 shares at a stated price of $0.0000, representing shares issued from performance stock units that vested for the 2023–2025 performance period.
On the same date, 41.519 shares were disposed of at $243.1900 per share to cover tax obligations through share withholding, rather than an open-market sale. After these transactions, he directly owned 1,369.746 shares of West Pharmaceutical Services common stock.
West Pharmaceutical Services VP and Chief Accounting Officer Chad Winters reported equity-related transactions involving company common stock. On
On the same date, Winters disposed of 50.579 shares at
West Pharmaceutical Services President and CEO Eric Mark Green reported several equity-related transactions. On February 17, 2026, he acquired 4,418.771 shares of common stock as a grant. On February 18, 2026, 1,318.810 restricted stock units, stemming from 2023–2025 performance stock units, converted into common stock on a one-for-one basis. To cover tax obligations, he disposed of 1,305.382 shares at
West Pharmaceutical Services senior vice president and chief HR officer Annette F. Favorite reported multiple equity transactions. On February 17, 2026, she acquired 441.957 shares of common stock through a grant or award and had 150.443 shares withheld to cover tax obligations. On February 18, 2026, she exercised 135.491 restricted stock units, converting them into the same number of common shares, with 35.757 shares withheld for taxes at prices of
West Pharmaceutical Services, Inc. filed its annual report detailing a global injectable drug-packaging and delivery business organized into Proprietary Products and Contract-Manufactured Products. Sales outside the U.S. represented 56.7% of 2025 consolidated net sales, underscoring its international exposure.
The company highlights concentration risk: its ten largest customers made up 47.6% of 2025 net sales, and one customer contributed 15.8% or
West employed about 10,800 people as of December 31, 2025 and continued quarterly dividends, raising the payout to
West Pharmaceutical Services SVP & CFO Robert W. McMahon reported equity award activity on February 11, 2026. He converted 4,230.525 restricted stock units into the same number of common shares at an exercise price of $0.
To cover tax obligations, 1,250.034 common shares were withheld at $246.16 per share, leaving 2,980.491 common shares held directly after the transaction. He also reported 8,462.052 restricted stock units remaining outstanding following these events.